3 Small-Cap Stocks with Questionable Fundamentals

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

The downside that can come from buying these securities is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. That said, here are three small-cap stocks to swipe left on and some alternatives you should look into instead.

Photronics (PLAB)

Market Cap: $2.22 billion

Sporting a global footprint of facilities, Photronics (NASDAQ:PLAB) is a manufacturer of photomasks, templates used to transfer patterns onto semiconductor wafers.

Why Does PLAB Fall Short?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 2.4% annually over the last two years
2. Estimated sales growth of 4.1% for the next 12 months is soft and implies weaker demand
3. High input costs result in an inferior gross margin of 35.9% that must be offset through higher volumes

Photronics’s stock price of $37.70 implies a valuation ratio of 18.7x forward P/E. If you’re considering PLAB for your portfolio, see our FREE research report to learn more.

Alta (ALTG)

Market Cap: $222.7 million

Founded in 1984, Alta Equipment Group (NYSE:ALTG) is a provider of industrial and construction equipment and services across the Midwest and Northeast United States.

Why Do We Pass on ALTG?

1. Muted 1.1% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
2. Cash burn makes us question whether it can achieve sustainable long-term growth
3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders

Alta is trading at $6.91 per share, or 6.4x forward EV-to-EBITDA. To fully understand why you should be careful with ALTG, check out our full research report (it’s free).

Baxter (BAX)

Market Cap: $11.25 billion

With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE:BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.

Why Do We Steer Clear of BAX?

1. Constant currency revenue growth has disappointed over the past two years and shows demand was soft
2. Earnings per share fell by 6% annually over the last five years while its revenue was flat, showing each sale was less profitable
3. Negative returns on capital show that some of its growth strategies have backfired, and its shrinking returns suggest its past profit sources are losing steam

At $21.80 per share, Baxter trades at 10.8x forward P/E. Dive into our free research report to see why there are better opportunities than BAX.

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.